MIMOTOPE INDUCED B-CELL ANTIBODIES FOR IMMUNO-ONCOLOGY

Leslie Chong | Chief Executive Officer
2H/2017
NOTICE: FORWARD LOOKING STATEMENTS

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Imugene Limited’s control. Important factors that could cause actual results to differ materially from any assumptions or expectations expressed or implied in this brochure include known and unknown risks. As actual results may differ materially to any assumptions made in this brochure, you are urged to view any forward looking statements contained in this brochure with caution. This presentation should not be relied on as a recommendation or forecast by Imugene Limited, and should not be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.
Imugene’s technology can induce a patient’s body to make its own specific antibodies that target cancer.
EXECUTIVE SUMMARY

- Two novel oncology platforms: B cell mimotope vaccines and small molecule arginine modulator
- Lead mimotope: HER-Vaxx Phase 1b/2 mimotope study in Her-2+ gastric cancer about to commence
  - POC demonstrated in Phase 1 Her-2+ breast cancer study – safety & immunogenecity established
- Mimotope candidate to be identified
- Arginine modulators in pre-clinical development
- Robust IP portfolios
- Outstanding scientific provenance from leading medical institutions & extensively published in peer journals
- Numerous milestone announcements & valuation inflection points over next 12-24 months
- Attractively priced against ASX and international peers
- Experienced management & board
A BETTER WAY TO MAKE ANTIBODIES TO TREAT CANCER?

IN A FACILITY

For example, Roche’s Herceptin

VS

USING B CELLS IN YOUR OWN BODY

B Cells are cells in the human body that naturally produce millions of antibodies

Teaching B cells to make antibodies using peptide mimotopes
A mimotope is a small molecule, often a peptide, which mirrors the structure of an epitope, the specific target an antibody binds to.

Because of this property, the mimotope induces an antibody response similar to the one elicited by the epitope.

A mimotope causes your B cells to produce an antibody copy of the antibody you want to “mimic”

Potential tool for selecting novel vaccine candidates against a variety of tumors

Technology can be used to copy any approved antibody on the market today
MIMOTOPE: PLATFORM TECHNOLOGY

**SELECTION OF MIMOTOPES**

A library of mimotopes can be interrogated with any monoclonal antibody to identify the mimotopes to which it binds.

**CREATION OF A VACCINE**

The selected mimotope or mimotopes can be used in isolation or combination to create a B-cell peptide therapy with the appropriate carrier system and adjuvant.

**IMMUNIZATION**

Immunization with the peptide will lead to the patients B-cells producing copies of the Ab you want to mimic.

**ENDOGENOUS AB PRODUCTION**

Successful delivery will result in endogenous Ab production with associated immune memory.

The mimotope platform has the potential to be part of the next wave of immuno-oncology products. It makes multi-level therapies against a combination of targets achievable.
ADVANTAGES OF MIMOTOPE INDUCED B-CELL BASED ANTIBODIES V. SYNTHETIC ANTIBODIES

<table>
<thead>
<tr>
<th>Issue</th>
<th>Natural B Cell Derived Antibodies</th>
<th>Monoclonal Antibodies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safety</td>
<td>Stimulates the immune system to produce natural Abs, potentially safer, as demonstrated by HER-Vaxx</td>
<td>Synthetic Ab, with side effects (including ventricular dysfunction, CHF, anaphylaxis, immune mediation)</td>
</tr>
<tr>
<td>Efficacy</td>
<td>Polyclonal Ab response reduces risk of resistance and potentially increases efficacy</td>
<td>Monoclonal Ab - single shot</td>
</tr>
<tr>
<td>Durability</td>
<td>Antibodies continuously produced a lasting immune response to inhibit tumor recurrence</td>
<td>Half life up to 12 days sometimes less</td>
</tr>
<tr>
<td>Usability</td>
<td>Potentially low numbers of vaccinations required per year</td>
<td>Requires regular infusion</td>
</tr>
<tr>
<td>Cost</td>
<td>Low cost of production enables greater pricing flexibility facilitating combinations and opening up additional markets</td>
<td>Expensive course of treatment &gt;USD100K per year in the US</td>
</tr>
</tbody>
</table>

B-Cell Vaccines offer a unique opportunity to intervene at multiple points in the immune system and create immune memory which enhances durability of response.
Multiple antibody therapies are approved to treat cancer, for example:

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Sales in 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Herceptin</td>
<td>&gt;US$6.7 billion</td>
</tr>
<tr>
<td>Perjeta</td>
<td>&gt;US$1.8 billion</td>
</tr>
<tr>
<td>Rituxan</td>
<td>&gt;US$7.3 billion</td>
</tr>
<tr>
<td>YERVOY®</td>
<td>&gt;US$1.0 billion</td>
</tr>
<tr>
<td>OPDIVO®</td>
<td>&gt;US$3.7 billion</td>
</tr>
<tr>
<td>KEYTRUDA</td>
<td>&gt;US$1.4 billion</td>
</tr>
</tbody>
</table>

Total monoclonal antibody market is currently at US$60 billion

- All of these antibodies are manufactured in a factory.

- Instead of infusing patients with antibodies synthesized in a factory, what if we can induce the patient’s own B-cells to make similar cancer-fighting antibodies using Imugene’s mimotope technology?
HER-Vaxx MIMOTOPE: MECHANISM OF ACTION

Peptides "mimic" the epitope

3 Peptides

HER-Vaxx Immunotherapy

B-cell Activation

HER-Vaxx Antibody Secretion

Via helper T-cells

Tumor Cell

HER-2/neu

EPITOPE = Antibody Binding Site

HER-Vaxx attacks the same target as the world's largest selling breast cancer drug Herceptin

For personal use only
HER-VAXX IS A Phase 1b/2 STAGE MIMOTOPE PEPTIDE THERAPY BEING DEVELOPED FOR HER2+ GASTRIC CANCER
PHASE 1 IN BREAST CANCER, COMPLETED AT MEDICAL UNIVERSITY OF VIENNA- SINGLE AGENT, NO CHEMO

**DESIGN**
- 10 patients
- All late stage breast cancer patients
- HER-2 +/++
- Life expectancy > 4 months
- Conducted at Medical University of Vienna

**RESULTS**
- Patients developed anti-HER-2 antibodies
- Induction of cytokines (Th1 biased; IFNγ)
- Induction of memory T & B cells post vaccination
- Reduction in T reg cells post vaccination, indicating strong vaccine response
- Antibodies induced displayed potent anti-tumor activity
- Promising results - Patients were end stage and not primary target group
- Reviewed in peer publication

**CLINICAL ENDPOINTS**
1. Safety and Tolerability
2. Immunogenicity: antibodies and cellular responses

HER-VAXX HAS BEEN OPTIMISED SINCE PHASE 1A BREAST CANCER STUDY

1st Generation
• Three separate B Cell epitopes delivered in virosomes (used in Phase 1a).

2nd Generation
• Incorporated the three B Cell epitopes into a single 49-mer peptide
• > 2x increase in antibody response in vivo compared to three single epitopes (extended patent life to 2030)

3rd Generation
• Changed the delivery system from virosomes to CRM197 (which gave CD4 T-Helper response), and added a montanide adjuvant
• >20x increase in antibody response in vivo (potentially extends patent life to 2036)
HER-Vaxx antibodies demonstrate anti-tumour effect by inhibiting HER-2+ gastric and breast cancer cell lines. Combination with Herceptin shows significantly higher inhibition than Herceptin alone.

*HER-2+ gastric cancer cells*

*HER-2+ breast cancer cells*

*BMC Cancer 2017, Wiedermann Feb. 2017*
PHASE 1B/2, IN GASTRIC CANCER

Phase 1b lead-in
- Open label
- ~Up to 18 patients in 3 cohorts of up to 6 pts per cohort
- Combination with chemo/cisplatin
- Endpoints:
  - Recommended Phase 2 Dose of HER-Vaxx
  - Safety: any HER-Vaxx toxicity
  - Immunogenicity (anti-HER-2 antibody titres)

Phase 2
- Open label
- ~68 patients from sites in Asia
- Combination with chemo
- Randomized
- Primary Endpoints:
  - Overall Survival
  - Progression-Free Survival
- Secondary endpoint:
  - Immune response

2H, 2017: Patients Enrolled
2H, 2017: Early Patient Data Available
2H, 2017: Interim Ph1b Patient Data Available
1H, 2018: Final Ph1b Patient Data Available
GASTRIC MARKET OPPORTUNITY

• Asia is the largest market for gastric cancer globally
• Gastric cancer is the second leading cause of cancer mortality in the world & its management, especially in advanced stages, has evolved relatively little
• ~20% patients with metastatic gastric cancer are HER-2 positive
• Surgery, chemotherapy, radiation & Herceptin are the key treatments
• In many countries, particularly Asia, chemotherapy such as capecitibine and 5-FU, is the standard of care, not Herceptin
MIMOTOPE B-CELL PEPTIDE THERAPY
MIMOTOPE PROPOSED DEVELOPMENT PATH 2017-2018

**Proposed Phase I Mimotope #1 Design**

- **Dose Finding**
  - Cohort 1: 3
  - Cohort 2: 3
  - Cohort 3: 3
  - Cohort 4: 3
  - Cohort 5: 3 - 6

- **Signal Seeking**
  - MTD
  - *Safety* 
  - *PK* 
  - *Tumor PD*

**Expansions Assumption**

- **Indication Expansion (12 patients)**
- **Proof of Concept**

**1H, 2017:** Mimotope Candidate (cont. dev of 2-3 additional candidate)

**1H, 2018:** CMC manufacturing

**1H, 18:** Formal pre-clinical

**2H, 2018:** Toxicology, immunotox, safety pharmacology

**2H, 2018:** GMP manufacturing

*For personal use only*
ARGININE MODULATORS
Arginine is a critical amino acid for the health of cancer fighting T-cells and depletion of it limits the effectiveness of T-cells to fight tumors.

- IMU’s A12 molecule increase the availability of arginine in the cellular environment

Proof of concept for A12 could be established as early as 2H 2017.

- New patent filed in the field of cancer and I-O, including combination with checkpoint inhibitors
- Commercially validated by Incyte’s I-O deal with Calithera’s Phase 1 arginine inhibitor CB-1158

### DEAL TERMS

- Worldwide rights for heme & oncology
- $45m up-front & $8m equity investment
- $420 million
- Co-fund development of CB-1158
Given that Arginine is a critical amino acid for the health of cancer fighting T-cells:

- In vitro effect of lead compound on human PBMC’s will readout T-cell cytokine changes
- Flow cytometry – ex-vivo analysis of CD4+ T cell proliferation and INF-γ. Will help elucidate key MOA
- Anti-tumour activity in 12 syngeneic mouse models
- Non-GLP PK and ADME assays
- Formal preclinical Tox/safety pharmacology
- GMP manufacture – CMC
- IND application

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Cancer Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>H22</td>
<td>Liver</td>
</tr>
<tr>
<td>MC38</td>
<td>Colon</td>
</tr>
<tr>
<td>EMT-6</td>
<td>Breast</td>
</tr>
<tr>
<td>Pan02</td>
<td>Pancreatic</td>
</tr>
<tr>
<td>CT26</td>
<td>Colon</td>
</tr>
<tr>
<td>B16F10</td>
<td>Melanoma</td>
</tr>
<tr>
<td>A20</td>
<td>Lymphoma</td>
</tr>
<tr>
<td>LL/2</td>
<td>Lung</td>
</tr>
<tr>
<td>B16BL6</td>
<td>Melanoma</td>
</tr>
<tr>
<td>RM-1</td>
<td>Prostate</td>
</tr>
<tr>
<td>Renca</td>
<td>kidney</td>
</tr>
<tr>
<td>MBT2</td>
<td>Bladder</td>
</tr>
</tbody>
</table>
A TEAM WITH TRACK RECORD IN DRUG DEVELOPMENT

Leslie Chong
Chief Executive Officer
• Over 19 years of oncology experience in Phase I - III of clinical program development
• Leadership role involvement in 2 marketed oncology products
• Previously Senior Clinical Program Lead at Genentech, Inc., in San Francisco

Dr Axel Hoos
Non-Executive Director
• Currently Vice President Oncology R&D at GlaxoSmithKline
• Previously Clinical Lead on Ipilumimab at Bristol-Myers Squibb
• Co-Director of the think-tank Cancer Immunotherapy Consortium

Paul Hopper
Executive Chairman
• International & ASX biotech capital markets experience particularly in immuno-oncology & vaccines
• Chairman of Viralytics, Founder & Director of Prescient, Founder of Imugene & Polynoma LLC, former Director pSivida, Somnomed & Fibrocell Science

Prof Ursula Wiedermann
Chief Scientific Officer
• Co-inventor of Her-Vaxx;
• Professor of Vaccinology at Medical University of Vienna

Dr Nick Ede
Chief Technology Officer
• Over 25 years peptide vaccine and drug development
• Former CEO Adistem, CEO Mimotopes
• VP Chemistry Chiron (now Novartis), Research Fellow CRC Vaccine Technology

Dr Anthony Good
Clinical Program Manager
• Over 15 years oncology & immunology experience.
  Active in the development of Viagra, Revatio, Lipitor, Selzentry and Somavert.
• Ex Pfizer Global Research and Development
BUSINESS STRATEGY AND PARTNERING OPPORTUNITIES

2018
Phase 1b Gastric Study

2018-2019
Phase 1b Mimotope + others

2018-2020
Big Pharma and/or biotech?
# FINANCIAL SUMMARY

## ASX:IMU

<table>
<thead>
<tr>
<th></th>
<th></th>
<th>$33.1M AUD, $25.7M USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Market Cap</td>
<td>(14 Jul/17)</td>
<td></td>
</tr>
<tr>
<td>Ordinary Shares</td>
<td></td>
<td>2.365 billion</td>
</tr>
<tr>
<td>12 month price range</td>
<td></td>
<td>0.7 cents – 2.1 cents AUD</td>
</tr>
<tr>
<td>Avg daily volume</td>
<td></td>
<td>2M shares (April-June 2017)</td>
</tr>
<tr>
<td>Investment to Date</td>
<td></td>
<td>~$15.2 m (public)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>~$ 5.5 m (VC)</td>
</tr>
<tr>
<td>Cash &amp; Equivalents</td>
<td></td>
<td>$5.7M as of April 2017</td>
</tr>
</tbody>
</table>

## Top 5 shareholders (as at May. 2017)

<table>
<thead>
<tr>
<th></th>
<th>No. of Shares</th>
<th>% Capital</th>
</tr>
</thead>
<tbody>
<tr>
<td>Platinum Asset Management</td>
<td>240,227,753</td>
<td>10.16%</td>
</tr>
<tr>
<td>National Nominees Limited</td>
<td>95,548,708</td>
<td>4.04%</td>
</tr>
<tr>
<td>Webinvest Pty Ltd</td>
<td>90,000,000</td>
<td>3.81%</td>
</tr>
<tr>
<td>Paul Hopper Executive Chairman</td>
<td>66,424,732</td>
<td>2.81%</td>
</tr>
<tr>
<td>Tisia Nominees</td>
<td>65,899,999</td>
<td>2.79%</td>
</tr>
</tbody>
</table>

## Options on issue (as at May. 2017)

<table>
<thead>
<tr>
<th></th>
<th>No of options</th>
<th>Exercise Price</th>
<th>Expires</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unlisted</td>
<td>49,000,000</td>
<td>$0.015*</td>
<td>Various dates (Nov 2017 to Sep 2020)</td>
</tr>
</tbody>
</table>

* Average
Definitive clinical data package from a Phase 1b and Phase 2 trial in gastric cancer

3-4 mimotope candidates. Move at least two mimotope candidates from pre-clinical to IND enabled and to complete one mimotope in a Phase 1 clinical trial

Candidate selection Develop at least one to pre-clinical proof of concept
# IMUGENE PIPELINE

<table>
<thead>
<tr>
<th>PROGRAM</th>
<th>MIMOTOPE IDENTIFICATION</th>
<th>IMMUNE CHARACTERIZATION</th>
<th>ID OF CANDIDATE</th>
<th>PRE-IND WORK</th>
<th>CLINICAL DEVELOPMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>HER-Vaxx</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HER-Vaxx /Her2 Combo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Mimotope #2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Mimotope #3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Her2 / *Mimotope Combo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combo #3?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arginine Modulator</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For personal use only

- 26 -
EXECUTIVE SUMMARY

- Two novel oncology platforms: B cell mimotope vaccines and small molecule arginine modulator
- Lead mimotope: HER-Vaxx Phase 1b/2 mimotope study in Her-2+ gastric cancer about to commence
  - POC demonstrated in Phase 1 Her-2+ breast cancer study – safety & immunogenecity established
- Mimotope candidate to be identified
- Arginine modulators in pre-clinical development
- Robust IP portfolios
- Outstanding scientific provenance from leading medical institutions & extensively published in peer journals
- Numerous milestone announcements & valuation inflection points over next 12-24 months
- Attractively priced against ASX and international peers
- Experienced management & board
SR. TEAM MEMBER ON MARKETED ONCOLOGY DRUGS
HERCEPTIN ® (TRASTUZUMAB)
MILD TREATMENT RELATED SIDE EFFECTS

• Diarrhea
• Redness or irritation at injection (IV) site
• Muscle/joint/back pain
• Stomach or abdominal pain
• Headache
• Sleep problems (insomnia)
• Nausea and vomiting (may be severe)
• Weight loss
HERCEPTIN ® (TRASTUZUMAB)
SERIOUS TREATMENT RELATED SIDE EFFECTS – BLACK BOX WARNING1

- CARDIOMYOPATHY: Herceptin can result in sub-clinical and clinical cardiac failure manifesting as CHF (congestive heart failure), and decreased LVEF (left ventricular ejection fraction).

- INFUSION REACTIONS: PULMONARY TOXICITY: Herceptin administration can result in serious and fatal infusion reactions and pulmonary toxicity.

- Anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome.

1. Herceptin Product Label – full prescribing information
Patient inclusion criteria
- Metastatic breast cancer
- HER2 +, ++
- ER/PR pos.
- Life expectance > 4 mo

Primary endpoint
- Safety & Tolerability

Secondary endpoint
- Immunogenicity
  - Specific antibodies
  - Cellular responses

### PATIENT CHARACTERISTICS – AGES 55-84 *

<table>
<thead>
<tr>
<th>Patient ID</th>
<th>Age</th>
<th>Metastatic disease since</th>
<th>Prior chemotherapy</th>
<th>Current antihormonal therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>55</td>
<td>Oct. 2006</td>
<td>no</td>
<td>Anastrozol</td>
</tr>
<tr>
<td>2</td>
<td>66</td>
<td>May 2004</td>
<td>yes (1 adj)</td>
<td>Fulvestrant</td>
</tr>
<tr>
<td>3</td>
<td>84</td>
<td>Mar. 1999</td>
<td>no</td>
<td>Anastrozol</td>
</tr>
<tr>
<td>4</td>
<td>79</td>
<td>Sept. 2003</td>
<td>no</td>
<td>Anastrozol</td>
</tr>
<tr>
<td>5</td>
<td>67</td>
<td>Apr. 2004</td>
<td>no</td>
<td>Fulvestrant</td>
</tr>
<tr>
<td>6</td>
<td>69</td>
<td>Sept. 2004</td>
<td>no</td>
<td>Anastrozol</td>
</tr>
<tr>
<td>7</td>
<td>60</td>
<td>Aug. 2002</td>
<td>yes (3 met)</td>
<td>Fulvestrant</td>
</tr>
<tr>
<td>8</td>
<td>76</td>
<td>Apr. 1999</td>
<td>no</td>
<td>Fulvestrant</td>
</tr>
<tr>
<td>9</td>
<td>63</td>
<td>Jun. 2006</td>
<td>yes (1 met)</td>
<td>Exemestan</td>
</tr>
<tr>
<td>10</td>
<td>70</td>
<td>Apr. 2008</td>
<td>No</td>
<td>Anastrozol</td>
</tr>
</tbody>
</table>

SAFETY AND TOLERABILITY – FEW GRADE 1 LOCAL REACTIONS, NONE SYSTEMIC*

<table>
<thead>
<tr>
<th>Patient ID</th>
<th>Local vaccination reaction grade</th>
<th>Systemic grade 3/4 toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1</td>
<td>no</td>
</tr>
<tr>
<td>2</td>
<td>0</td>
<td>no</td>
</tr>
<tr>
<td>3</td>
<td>0</td>
<td>no</td>
</tr>
<tr>
<td>4</td>
<td>1</td>
<td>no</td>
</tr>
<tr>
<td>5</td>
<td>1</td>
<td>no</td>
</tr>
<tr>
<td>6</td>
<td>0</td>
<td>no</td>
</tr>
<tr>
<td>7</td>
<td>0</td>
<td>no</td>
</tr>
<tr>
<td>8</td>
<td>0</td>
<td>no</td>
</tr>
<tr>
<td>9</td>
<td>1</td>
<td>no</td>
</tr>
<tr>
<td>10</td>
<td>0</td>
<td>no</td>
</tr>
</tbody>
</table>

PHASE 1 SECONDARY ENDPOINT – IMMUNOLOGIC RESPONSES

ANTIBODY RESPONSES

• 8/10 developed significant anti-peptide antibody levels
• In all but one the antibodies were also directed against Her-2/neu
• The majority also showed a 4-fold increase in influenza titres (HI)

WESTERN BLOT ANALYSIS DEMONSTRATING INCREASE OF HER-2/NEU-SPECIFIC IgG POST-VACCINATION IN PATIENT:
(lane 1) Polyclonal rabbit anti Her-2/neu antibody was used as positive control
(lane 2) Serum of a healthy volunteer as negative control
(lane 3) Serum prior
(lane 4) After completed vaccinations

**REDUCTION IN REGULATORY T CELLS**

- Significantly higher number of CD4+Foxp3+ regulatory T cells in tumour patients than healthy controls
- Vaccination significantly reduced T reg cells in both groups

ENCOURAGING IMMUNOGENICITY, EVEN AT LOW DOSE, AND IN PATIENTS AGES UP TO 84 YEARS, WITH NO CARDIOTOXICITY

Antibody and cellular responses in human

<table>
<thead>
<tr>
<th>Pat. #</th>
<th>Peptide-specific ab P4, P6, P7</th>
<th>HER2-specific ab</th>
<th>Infl. HIT</th>
<th>IL-2, IFNγ, TNF</th>
<th>T reg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>↑ ↑ ↑</td>
<td>↑</td>
<td>-</td>
<td>- - -</td>
<td>↓</td>
</tr>
<tr>
<td>2</td>
<td>↑ ↑ ↑</td>
<td>↑</td>
<td>↑</td>
<td>↑ ↑ ↑</td>
<td>↓</td>
</tr>
<tr>
<td>3</td>
<td>↑ ↑ ↑</td>
<td>↑ (+/-)</td>
<td>-</td>
<td>↑ -</td>
<td>↓</td>
</tr>
<tr>
<td>4</td>
<td>↑ ↑ ↑</td>
<td>↑</td>
<td>↑</td>
<td>- ↑ ↑</td>
<td>↓</td>
</tr>
<tr>
<td>5</td>
<td>↑ ↑ ↑</td>
<td>↑</td>
<td>↑</td>
<td>↑ ↑ ↑</td>
<td>↓</td>
</tr>
<tr>
<td>6</td>
<td>- - -</td>
<td>-</td>
<td>-</td>
<td>↓ ↓ ↓</td>
<td>↓</td>
</tr>
<tr>
<td>7</td>
<td>↑ ↑ ↑</td>
<td>↑</td>
<td>↑</td>
<td>- - -</td>
<td>↓</td>
</tr>
<tr>
<td>8</td>
<td>↑ ↑ ↑</td>
<td>↑ (+/-)</td>
<td>↑</td>
<td>↑ ↑ -</td>
<td>↑</td>
</tr>
<tr>
<td>9</td>
<td>↑ +/- +/−</td>
<td>↑</td>
<td>↑</td>
<td>↑ ↑ ↑</td>
<td>↓</td>
</tr>
<tr>
<td>10</td>
<td>- - -</td>
<td>-</td>
<td>-</td>
<td>+/- ↓ +/-</td>
<td>↓</td>
</tr>
</tbody>
</table>

HER-Vaxx breast cancer vaccine – Phase 1 trial 10 µg group

- Immunogenicity in 8/10 patients in Phase 1 study with 10 µg of peptide antigen
- Good correlation with cellular responses (cytokines)
- Safe and well tolerated, in particular no cardiotoxicity
- Protective efficacy of peptides demonstrated in preclinical tumor model in mice showing delay of onset and reduced tumor growth

TUMOR GROWTH INHIBITION IN VIVO*

• Prolonged time to disease progression

• Immunization of c-neu transgenic mice (recognized HER2 cancer model) with tetanus toxoid-conjugated peptides P4, P6 and P7

• Vaccinated animals show significant delay in tumor onset and reduced growth kinetics

• Co-administration of IL-12 further improves the vaccine performance


For personal use only

Preclinical study with tetanus toxoid–conjugated peptide antigens

- 37 -
**MIMOTOPE**

EPITOPE = Antibody Binding Site

HER2\(^+\) Cancer Cell

HER-2 Receptor

Anti HER-2 Antibody

Patient’s B Cells make antibodies against HER-2

Peptides “mimic” the epitope

Mimotope Peptides

For personal use only
In the mouse model the new formulation sees circulating antibodies maintained for 6 months which equates to many years in humans.
Leslie Chong
Chief Executive Officer
leslie.chong@imugene.com
+61 458 040 433